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Abstract
Biologic therapies have revolutionised disease control in patients with rheumatoid arthritis (RA). Theoretically,
they have the potential to influence co-morbid disease associated with RA through better control of systemic
inflammation. Conversely, co-morbidity may occur as an adverse effect of the drugs. The latest evidence from
observational data shows an increased risk of infection in the first 6 months of treatment with tumour necrosis
factor inhibitor (TNFi) therapies and potentially other biologic therapies. Rates of infection after the first 6 months
decrease and become comparable to patients with RA treated with conventional synthetic disease modifying
anti-rheumatic drugs (csDMARDs). TNFi also appear to reduce the risk of cardiovascular disease in these patients, in
particular ischaemic heart disease. TNFi treatment may be associated with a small increase in the risk of developing
squamous cell carcinoma of the skin; in terms of other cancers, rates appears to be no different to those seen in
patients treated with csDMARDs. There is a paucity of data on the impact of other biologic therapies and the effect
of all biologic therapies on other common co-morbidities.
Background
Biologic therapies, or biologic disease modifying anti-
rheumatic drugs (bDMARDs), have transformed disease
control and outcomes for patients with rheumatoid arth-
ritis (RA) since they were introduced early this century.
RA is a systemic inflammatory disorder of the immune
system which predominantly affects the joints. However,
it also affects other body systems either directly or indir-
ectly [1]; thus, the impact of bDMARDs is not confined
to the joints. Infections [2, 3] and certain types of cancer
[4] occur more frequently in patients with RA. Similarly,
both fatal and non-fatal cardiovascular diseases (CVD)
are approximately 1.5–2-fold more common in patients
with RA than in the general population [5, 6]. The in-
creased mortality seen in RA is thought to be driven in a
large part by co-morbidity, in particular cardiovascular
disease (CVD) [5]. It has been suggested that many of
these co-morbidities are a consequence of a high cumu-
lative burden of systemic inflammation [7, 8]. There-
fore, it might be hypothesised that better disease
control achieved through new, more potent treatments
may reduce co-morbidity. Further, some of these co-
morbidities (in particular infections and CVD) may be
exacerbated by glucocorticoid use, and better disease
control may enable reduction in glucocorticoid usage in
these patients. On the other hand, co-morbidity in pa-
tients with RA may occur as an adverse effect of medica-
tion, in particular immune suppression. Thus, bDMARDs
might be associated with an increased incidence of some
diseases.
The European League Against Rheumatism (EULAR)
has recently highlighted six key comorbidities for sys-
tematic screening in routine care [9]: infections, CVD,
malignancy, gastrointestinal disease, osteoporosis and
depression. In this review we explore the evidence for
an association between biologic use and a change in
any of these co-morbidities. Randomised controlled trials
(RCTs) provide relatively limited information because of
their strict inclusion and exclusion criteria (often exclud-
ing patients with prevalent co-morbidity) and short
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duration. We therefore focus on observational, real world
data. Most published evidence relates to infection, CVD
and cancer. As tumour necrosis factor inhibitors (TNFi)
were the first bDMARDs to enter clinical practice, they
have been the most widely studied biologic drugs.
Infection
Serious infections (SIs) are infections which lead to hos-
pitalisation, intravenous antibiotics or death. As a dis-
ease of dysregulated immune function, RA is associated
with an increased risk of SI [10–12]. Glucocorticoids
and conventional synthetic DMARDs (csDMARDs) have
broad immunosuppressive properties and also predis-
pose to SIs [10, 12–14]. Observational data suggest that
the baseline risk of SI in biologic-naïve patients with RA
is approximately double that of the general population
[11, 12, 15]. BDMARDs target key cytokines and cells
involved in both maintaining inflammation and fighting
infection. Therefore, it is likely that bDMARDs will in-
crease the risk of SI. Conversely, longer term use of
bDMARDs might reduce infection risk by lowering the
patient’s requirement for glucocorticoids.
Tumour necrosis factor inhibitors
Individual early randomised controlled trials (RCTs) of
TNFi did not show a statistically significant increased
risk of SI. However, a meta-analysis of nine RCTs of
adalimumab (ADA) and infliximab (INF), published in
2006, found a doubling of risk of SI compared to the
control arms of the trials [16]. The most recent systematic
review and meta-analysis of 106 RCTs of nine biologic
therapies found an odds ratio of 1.31 (95% confidence
intervals (CI) 1.09, 1.58) for standard dose bDMARDs
versus conventional synthetic disease modifying anti-
rheumatic drug (csDMARDs) [17], which translated to an
additional six SIs per 1000 person-years in patients taking
bDMARDs compared to csDMARDs alone. There was no
apparent difference in risk between bDMARDs.
The latest systematic review of observational data iden-
tified nine studies of SI in patients treated with TNFi.
Adjusted hazard ratios (HRs; compared to csDMARDs)
ranged from 1.1 to 1.8 [18]. Some of the variation between
studies can be attributed to varying periods of follow-up
or ‘time at risk’ [19]. It is now established that the high-
est risk is within the first 6 months of therapy with a
gradual decline thereafter [19–21]. Around two-thirds
of the decline can be attributed to ‘depletion of suscep-
tibles’, i.e. patients who experience an SI then stop TNFi
therapy, and one-third to an improvement in physical
function and a decrease in steroid dosage [22]. The
most common sites of SI are the lower respiratory tract
followed by skin and soft-tissue [20, 23].
Not all RA patients treated with TNFi are at the same
risk for SI. The German Biologics Register (RABBIT)
found that treatment with ≥7.5 mg glucocorticoid daily,
age greater than 60 years, chronic renal or lung disease,
more than five previous csDMARD failures and previous
SI were risk factors for the development of SI [22]. Inter-
estingly, the same register has very recently shown that
the risk of both sepsis and mortality following an SI is
lower in patients with RA exposed to bDMARDs com-
pared to csDMARDs [24].
Tuberculosis A case of tuberculosis (TB) was reported in
a phase III trial of INF in 1999 [25]. An increased risk of
TB and other granulomatous diseases was identified in pa-
tients treated with the monoclonal antibodies INF and
ADA, initially through spontaneous reporting to national
pharmacovigilance programmes [26], then subsequently in
the Spanish BIOBADASAR [27] and other observational
registers (summarised in [28]). Most cases of TB occurred
within 6 months of starting INF, suggesting re-
activation of latent TB. The British Society for Rheuma-
tology Biologics Register for Rheumatoid Arthritis
(BSRBR-RA) reported 40 cases of TB following TNFi
(crude incidence rate 118/100,000 person-years); 62%
were extra-pulmonary and ten resulted in death [29].
Although rates were higher in INF- and ADA-treated
patients, cases did occur in etanercept (ETN)-treated
patients. This and other reports led to the introduction
of a number of national guidelines for screening for
and treatment of latent TB with a subsequent reduction
in the rates of TB [30]. Data from RCTs suggest that
the risk of TB may be higher in certolizumab pegol-
and golimumab-treated patients [28]; however, most
cases came from countries with a high background
prevalence of TB. Results from observational data are
awaited but clearly the background risk of TB is an im-
portant consideration when making decisions about
biologic therapy in RA.
There is also a small increase in risk of other opportun-
istic infections, including legionellosis, non-tuberculous
mycobacteria, listeriosis, salmonellosis and nocardiosis. As
with SI and TB, the risk is highest in the early months
after TNFi initiation [31].
Herpes zoster The risk of reactivation of herpes zoster
(HZ; shingles) is increased in patients with decreased
cell-mediated immunity. An increased risk of HZ has
been reported by the German Biologics Register [32],
the US Veteran’s Administrative Database [33] and the
BSRBR-RA [34]; further, a 1.6-fold increase in risk of HZ
was found in a systematic review and meta-analysis
summarising published data up to March 2013 [35].
However, a study of 36,212 RA patients (24,384 initiating
TNFis) from four US automated databases found no
difference in the risk of HZ in patients initiating TNFi
compared to those initiating csDMARDs after adjusting
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for propensity score [36]. Increasing age and glucocortic-
oid dose greater than 10 mg daily were additional risk
factors for HZ in all these studies [28, 36].
Other bDMARDs
Less is known, particularly from observational studies,
about the infection risk associated with non-TNFi
bDMARDs. The most recent systematic review and
meta-analysis of RCT data suggests that the overall risk
of SI does not differ between biologic therapies when
used in standard doses, but is approximately 30%
higher than in patients treated with csDMARDs alone
[17]. A recent observational study of US veterans with
RA found similar rates of SI in patients treated with ri-
tuximab (RTX) or abatacept (ABT) to ETN [37]. RTX
acts by depleting pre-B cells and as a consequence leads
to reduced levels of IgG. Approximately 4% of patients
develop persistent hypogammaglobulinaemia following
repeated courses of RTX [38]. These patients, who tend
to be older with more co-morbidity, have a higher risk
of SI.
There is no signal of an increased risk of TB with RTX,
ABT or tocilizumab (TCZ) within the context of RCTs.
There may be a slight increase in the risk of progressive
multifocal leukoencephalopathy in patients treated with
RTX [39].
Cardiovascular disease
CVD is increased in patients with RA [5–7, 40]. This as-
sociation is partly attributable to an increased prevalence
of traditional cardiovascular (CV) risk factors such as
smoking [41], abnormal lipid profiles [42] and high body
fat:muscle mass ratio [43]; partly to shared genetic risk
factors [44, 45]; and partly to the effect of systemic
inflammation on the vasculature [40, 46, 47]. This link
between inflammation and atherosclerosis suggests CVD
risk may be particularly responsive to RA disease control.
There are data to suggest that successful disease control
improves surrogate markers of CVD, such as endothelial
dysfunction and carotid intimal media thickness [48–50].
A recent study using data from the Consortium of
Rheumatology Researchers of North America (CORRONA)
found that a ten-point reduction in the Clinical Disease
Activity Index (CDAI) [51] over a median of 2.7 years
was associated with a 21% reduction in risk of CV
events [52]. Similarly, a recent nested case–control
study from Germany demonstrated that levels of sys-
temic inflammation, measured by C-reactive protein
and erythrocyte sedimentation rate, were higher in
myocardial infarction (MI) cases compared to controls
and also that treatment of CV comorbidity was lower in
MI cases [53]. Another, much smaller, case–control
study from Germany of patients with RA and heart
failure demonstrated that patients with heart failure
had more active RA than controls [54]. There may be
treatment specific effects; for example the use of
methotrexate (MTX), the anchor csDMARD in the
treatment of RA, has been associated with up to 70%
reduction in mortality and, in particular, CV mortality
[55]. In addition some data suggest effective treatment
with any csDMARD reduces the risk of CVD [56].
Tumour necrosis factor inhibitors
A systematic review and meta-analysis, published in
2011, of observational cohort data found an overall 54%
reduction in the risk of all CV events in TNFi users
compared to patients taking csDMARDs [57]. National
drug registers in both Sweden and the UK have reported
a reduction in risk of CVD in patients who show a good
response to TNFi therapy compared to non-responders
[58, 59]; in addition, longer duration of therapy appears
to reduce the risk of CV events [60]. A recent study
from the BSRBR-RA in the UK, which linked registry
data to a national audit of MI for event verification,
demonstrated that patients with RA taking their first
TNFi had a 40% decrease in rates of MI compared to pro-
pensity score-matched csDMARD users [61]. Interest-
ingly, in similar analyses, rates of stroke were equivalent in
TNFi users compared to those taking csDMARDs (HR
0.99; 95% CI 0.54, 1.81) [62]. This may be because strokes
are less common than MIs and so the study lacked the
power to detect a difference; alternatively, it may be that
improved RA disease control does not translate to fewer
strokes or that any improvement is balanced out by an
increased risk conferred by the drugs themselves.
Reports on the association between TNFi therapy and
heart failure have been conflicting. After finding increased
levels of TNF in patients with heart failure, trials were
conducted using TNFi as treatment for heart failure
[63, 64]; none demonstrated benefit and one reported
worse outcomes in patients treated with TNFi [64].
Consequently, a ‘black box’ warning was introduced not
to use these medications in patients with pre-existing
heart failure. An early study in patients with RA
suggested a reduction in the rates of new onset heart
failure in TNFi users [65], but later data showed a non-
statistically significant trend towards increased rates of
incident heart failure [66]. The most recent data from
the US suggest similar rates of heart failure in new
TNFi users and new users of csDMARDs (HR 0.85;
95% CI 0.63 to 1.14) but identified that such a differ-
ence may have existed prior to the introduction of the
black box warning in 2002 [67]. This study also noted a
dose-dependent association between glucocorticoid use
and heart failure. Importantly, however, the authors
acknowledged that they were unable to adjust for
potential differences in baseline disease severity between
the TNFi and csDMARD groups as this information was
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not collected. The German RABBIT register also found
similar rates of heart failure in TNFi compared to
csDMARD users [68] and a dose-dependent association
with glucocorticoids. The authors of that study suggest
that the overall effect of TNFi is more beneficial (through
improved control of disease activity and reduced need for
glucocorticoids) than harmful.
Other bDMARDs
Observational data are limited regarding the relationship
between non-TNFi bDMARDs and CVD in patients with
RA. The largest study to date used administrative claims
data in the US to compare rates of CVD between patients
with RA taking different bDMARDs [69]. They included
over 47,000 patients and found rates of CVD were higher
in patients treated with TNFi compared to ABT (HR 1.28;
95% CI 1.04 to 1.56). A number of other studies have pro-
vided some potential data but are insufficient to draw firm
conclusions. A study from the German RABBIT registry
found improved all-cause mortality in RTX users com-
pared to csDMARD users [70]. This study did not exam-
ine CV mortality specifically; however, given that it is the
most common cause of mortality in RA, we might infer a
possible effect of RTX on CVD. Some small pilot studies
have shown beneficial effects of RTX on endothelial dys-
function and lipid profiles [71, 72]; conversely, the reduced
circulating IgM levels associated with long-term treatment
with RTX may confer a pro-atherogenic effect [73]. Par-
ticular concerns exist regarding CV event rates in patients
receiving TCZ, as IL-6 blockade is associated with in-
creased levels of total cholesterol and high-density and
low-density lipoproteins [74]. However TCZ, has only
been widely available in clinical practice since 2010 and
therefore insufficient observational data have accumulated
to address this question. A post hoc analysis of pooled
data from RCTs and open label extension studies found
that higher levels of disease activity and joint counts
amongst patients treated with TCZ were associated with
CV events but changes in lipid parameters were not [74].
A very small study from Norway identified improvements
in pulse wave velocity (another surrogate marker for
CVD) in 36 patients taking RTX and TCZ over 12 months,
with no change in patients taking ABT [75]. However,
given the small number of patients and limited follow-up,
it is difficult to draw strong conclusions from these data
about long-term CV effects.
Cancer
Patients with RA have an increased risk of cancer com-
pared to the general population, with a meta-analysis
published in 2015 by Simon et al. [76] showing a small,
statistically significant increase of 9% in the overall risk
of malignancy in patients with RA.
In terms of specific cancers, an increased risk of lymph-
oma is well recognised in patients with RA [77]. This risk
is greatest in patients with the highest cumulative burden
of disease activity [8]. The type of lymphomas seen in pa-
tients with RA suggests an underlying immune deficiency
profile prone to lymphomagenesis [77]. Even prior to the
introduction of TNFi therapies, some lymphoma events
were linked to the use of csDMARDs, in particular cyclo-
phosphamide, azathioprine and MTX, in the treatment of
RA [78]. The meta-analysis by Simon et al. found in-
creased rates of lymphoma as expected, but additionally
identified a greater risk of lung cancer (which may in part
be accounted for by smoking, a shared risk factor for
RA and lung cancer [79]) and a decreased risk of colo-
rectal cancers in patients with RA compared to the
general population. A study from the UK, published in
2013, also identified an increased incidence of lymph-
oma and lung cancer but showed a reduction in pros-
tate and cervical cancers in patients with RA [80]. In an
administrative claims database in South Korea, there
was again an increased risk of lymphoma but lower
rates of gastric cancer [81].
A number of studies have found an increased occur-
rence of non-melanoma skin cancer (NMSC) in RA com-
pared to the general population [82–84]. By contrast, it
is unclear whether RA is associated with malignant
melanoma. There is a well-documented link between
the immunocompromised host and melanoma, with
evidence from patients with AIDS and post organ
transplant [85, 86]. However, data in patients with RA
taking csDMARDs have been inconsistent [80, 87].
Interestingly, a study from Australia, which has the
highest background incidence of melanoma worldwide,
found an increased risk of melanoma in MTX users
compared to the background population [88]. In the
meta-analysis by Simon et al. [76] the pooled standar-
dised incidence rate for melanoma was significantly
higher in RA patients, although the authors noted that
few of the individual studies found a statistically signifi-
cant increased risk.
Tumour necrosis factor inhibitors
As TNF is known to have anti-tumour effects, there
were initial concerns that TNF inhibition could increase
cancer incidence [89]. Data on incident malignancies in
the TNFi RCTs were mixed, with some earlier individual
trials and meta-analyses appearing to show an increased
risk of cancer [16, 90]. However, more recent systematic
reviews and meta-analyses have not been able to repli-
cate this finding [84, 91]. A systematic review by Askling
et al. [91], published in 2011, explored the potential
cause of these different results. They noted that previous
meta-analyses did not include all of the published trials,
that the number of events in both treatment and control
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arms was low and that the definitions of cancer across
individual studies may not be comparable. They attempted
to address these issues in their meta-analysis. The authors
were provided with patient level data from each study
sponsor with more detailed information on study de-
sign, patent information and treatment details than was
available in the published reports. Cancer events were
identified by a search of each study sponsor’s clinical
and safety database, which allowed the same definition
of a cancer to be used across all studies. They found no
difference between cancer rates across the three TNFi
studied (INF, ETN and ADA), but did find differing
rates of cancer in respective control arms.
As a result of the initial concerns, patients with a history
of prior cancer were excluded from the majority of
TNFi RCTs and, post-licensing, TNFi therapy was felt
to be contra-indicated in patients with a previous ma-
lignancy. Therefore, information is limited on the recur-
rence of cancer in patients with prior malignancy treated
with TNFi. Nevertheless, recent studies from administra-
tive claims databases in the US and the Swedish ARTIS
register have reported no increase in recurrent cancers in
TNFi-treated versus biologic-naïve patients with similar
history of prior malignancy [92, 93]. These studies are also
supported by data from the British and German registries
[94, 95]. Notably, all studies were based on small numbers
of cases.
Regarding specific malignancies, the risk of lymphoma
in TNFi users has been widely studied. However, as
lymphoma is relatively rare, studies have struggled to
identify sufficient cases of lymphoma to reach robust con-
clusions. Observational studies from the UK, the US and
Sweden have examined the potential associated between
TNFi and lymphoma in patients with RA [4, 96–99]. A
study from South Sweden, published in 2005, reported a
large, but non-significant, relative risk of lymphoma of 4.9
(95% CI 0.9, 26.2) in patients treated with TNFi compared
to csDMARDs. Two US studies using the National Data
Bank for Rheumatic Diseases (NDB), found similar rates
of lymphoma in TNFi users compared to other patients
with RA [4, 97]. However, the Swedish and US studies
were limited by potential confounding by indication, i.e.
patients with more severe disease are more likely to be
prescribed TNFi. This was not adjusted for at all in the
first NDB publication [4]. The Southern Swedish and
second NDB publication adjusted for the baseline Health
Assessment Questionnaire score [97], which is more a
measure of disability than disease activity and therefore
there may have been residual confounding. The BSRBR-
RA study used propensity score matching to account for
confounding by indication and other imbalances between
baseline covariates between TNFi- and csDMARD-treated
patients; they reported an equivocal HR for lymphoma of
1.00 (95% CI 0.56, 1.80) [96]. The national Swedish ARTIS
registry also found no increased risk of lymphoma in
TNFi-exposed compared to csDMARD-exposed patients
[98]. Nevertheless, all of these studies remain potentially
underpowered, either through insufficient person-years of
observation or the low number of events. A recent
EULAR initiative performed a joint analysis with data
from 11 registers which has been published only as an ab-
stract so far [100]. With some 600,000 patient-years of ex-
posure no increased risk was found. The results are
reassuring not only concerning the overall incidence of
lymphomas but also the spectrum of subtypes.
Data from national European registries in the UK,
Germany and Denmark have consistently demonstrated
no increased occurrence of solid cancers in patients
treated with TNFi versus those treated with csDMARDs
[95, 101, 102]. These data are also supported by an older
study from the NDB in the US [103].
The risk of skin cancer appears to be unaltered by TNFi
therapy. A meta-analysis of observational and long-term
extension studies in 2012 by Le Blay et al. [84] found no
increase in NMSC in TNFi users compared to csDMARD
users (pooled odds ratio 0.79; 95% CI 0.62, 1.02). Subse-
quent studies from the DANBIO registry in Denmark and
the BSRBR-RA also found no difference in incidence of
NMSC rates between TNFi and csDMARD users [83,
102]. However, the most recent study from Sweden, the
largest to date with over 2800 NMSCs, did identify a small
increase in the risk of squamous cell carcinoma (SCC),
but not basal cell carcinoma, in TNFi users compared to
those taking csDMARDs [82]. The studies from Denmark
and the UK comprised mostly basal cell carcinomas and
relatively few SCCs and so may have been underpowered
to detect a small increase in SCC. The EULAR initiative
mentioned above also pooled data from 11 observational
registries across Europe in order to explore the risk of
malignant melanoma in TNFi versus csDMARD users
[104]. This study captured data on over 130,000 patients
over close to 580,000 patient-years follow-up. The overall
standardised incidence ratio, adjusted for calendar year,
and age and sex standardised to the reference population
of each country, was higher in the ever TNFi-exposed
versus biologic-naïve patients at 1.1 (95% CI 0.9, 1.4), but
this did not reach statistical significance.
Other bDMARDs
A small number of studies have investigated the risk of
malignancy in patients treated with other bDMARDs.
Simon et al. [105] compared rates of malignancy in the
RCT data for ABT with rates seen in five observational
cohorts of patients with RA taking csDMARDs. They
found the standardised incidence ratios were no different
in the ABT user group. Similarly, Solomon et al. [106]
investigated the risk of malignancy in a range of biologic
and csDMARD users compared to MTX users and found
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lower rates of malignancy in TNFi users but equivalent
rates (with wide confidence intervals) in patients treated
with RTX and ABT. Scott et al. [107] examined rates of
recurrent NMSC in patients with RA or inflammatory
bowel disease across a number of immunosuppressive
therapies. Rates of recurrence were similar in ABT and
RTX users compared to MTX users. The number of
events in each treatment group was small and may have
been underpowered to detect a true difference. Similarly,
the collaborative European project described above found
no increase in the risk of malignant melanoma in RTX,
ABT and TCZ users compared to biologic-naïve patients
[104]; again, both the number of events and total follow-
up time were small.
Other comorbidities: gastrointestinal disease, depression,
osteoporosis
Gastrointestinal (GI) disease is an important co-morbidity
in RA partly due to side effects of older medications.
Non-steroidal anti-inflammatory drugs (NSAIDs) and
glucocorticoid use are associated with peptic ulcer disease
and GI perforation [108, 109]. A number of registries have
investigated the effect of TNFi and other bDMARDs on
GI perforation [109–111] with no association identified,
although this outcome is rare and the individual studies
are probably underpowered. Curtis et al. [109] noted that
70% of the patients who experienced a GI perforation
were either taking glucocorticoids or had a history of
diverticular disease; similarly, in the BSRBR-RA the rela-
tive risk for GI perforation was nearly three times greater
in patients taking glucocorticoids compared to those who
were not [110]. Van Vollenhoven et al. [112] summarised
the risk of diverticular perforation in RCTs of TCZ. The
reported rates appeared to be slightly higher than rates
seen from other studies with TNFi and csDMARDS [113].
Although this study was published in abstract form only,
recent observational data from two studies also support
an increased risk of GI perforation in patients treated with
TCZ compared to those treated with other bDMARDs
and csDMARDs [107, 114].
Data are very limited on the relationship between
bDMARDs and depression. Depression is common in
patients with RA [115–117] and is higher compared to
the general population [118]. In these patients, depres-
sion is associated with levels of pain, disability and fa-
tigue [116, 119, 120]. Few studies have investigated the
impact of treatment of RA on depression. A study from
the BSRBR-RA examined the longitudinal relationship
between TNFi use and fatigue [119]. They found that,
although fatigue improves following treatment [119], a
large proportion of patients report residual fatigue
despite clinical remission [121]. A meta-analysis of
RCT data found no difference in levels of fatigue be-
tween patients treated with TNFi and those treated with
csDMARDs [122]. However, although depression and
fatigue are similar constructs, they are not identical and
thus we cannot make direct inferences about depres-
sion from these findings. A biological link has been
postulated between increased levels of IL-6 and depres-
sion [123]. However, trials of TCZ as a treatment for
depression have yet to be conducted and there are no
observational data to support such a link.
Again, data are limited on the relationship between
bDMARDs and bone health. RA is a recognised risk
factor for the development of osteoporosis and both longer
disease duration and treatment with glucocorticoids en-
hance that risk [124–126]. A few small studies have sug-
gested bone remodelling may improve with TNFi use
[127–129]. However, larger observational studies have
failed to find a reduction in fracture rates or improvement
in bone density in TNFi users versus non-users. Coulson et
al. [130], using data from the CORRONA registry, found
that incident fracture rates were not associated with
TNFi or csDMARD treatment, although they were
higher in glucocorticoid users compared to non-users.
Roussy et al. [131] investigated the impact of bDMARDs
(including TNFi, RTX, ABT and anakinra) in a nested case
control study of a Canadian claims database. As with the
CORRONA study, they found no evidence of an associ-
ation between sustained recent exposure to biologic drugs
and non-vertebral fracture rates.
Conclusions
The impact of biologic therapies on outcomes for pa-
tients has been substantial in terms of their disease con-
trol. In addition it appears that TNFi at least can
improve some of the burden of comorbidity associated
with the disease, particularly CVD. In terms of de novo
cancer, results have also generally been reassuring. There
may be a small risk of SCC of the skin in patients taking
bDMARDs for the first time [82], but this remains so far
an isolated signal. Studies of lymphoma remain under-
powered. However, if a strong signal existed it should
have been identified by the existing literature and there-
fore it is reassuring that any increased risk from TNFi, if
present, is likely to be small. Equally, the small number
of studies which have investigated recurrence of cancer
suggest TNFi may be safe in this population. There is an
increased risk of serious infections in the first 6 months
of treatment with TNFi (and probably all bDMARDs),
but this diminishes after this time for those who remain
on treatment.
There remains a paucity of data on the impact of TNFi
on other common comorbidities such as depression, GI
disease and osteoporosis. Further, newer biologic agents
with different mechanisms of action to TNFi, such as
RTX, ABT and TCZ, have not been studied in sufficient
detail to draw firm conclusions about their effects.
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